Open AccessCyclin C: A new responser for chemosensitivity in cancer
Author(s) -
Fang Shuai,
Jin Xiaofeng,
Zhou Chengwei,
Gong Zhaohui
Publication year - 2022
Publication title -
clinical and translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2001-1326
DOI - 10.1002/ctm2.833
Subject(s) - cisplatin , cancer research , chemotherapy , cyclin d1 , cancer , mitochondrion , mitochondrial fission , medicine , cancer cell , cyclin , cyclin d , oncology , chemistry , biology , microbiology and biotechnology , cell cycle
The resistance to cisplatin‐based chemotherapy is a common cause of poor prognosis in cancer patients. Cisplatin stimulation causes cyclin C translocating to mitochondria, and in turn induces mitochondrial fission. However, little is known about the role of cyclin C in mitochondrial dysfunction in cancer cells challenged with cisplatin. In the present commentary, we bring to the attention of readers the recent report by Jiang et al which revealed the importance of ubiquitylation and translocation of cyclin C in gastric cancer cells in response to cisplatin stimulation for mitochondrial stability. This finding provides new insights into exploring the novel mechanisms of chemoresistance and developing the new chemotherapy synergistic agents in the era of precision oncology.